Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients (Q38749966)

6 September 2017

title

Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients (English)

1 reference

6 September 2017

1 reference

1 reference

4

Jean-Charles Soria

0 references

Manfred Dietel

series ordinal

3

object named as

Manfred Dietel

1 reference

6 September 2017

Marius Ilie

1

1 reference

6 September 2017

Véronique Hofman

series ordinal

2

1 reference

6 September 2017

Paul Hofman

series ordinal

5

1 reference

6 September 2017

publication date

25 February 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

468

1 reference

6 September 2017

issue

5

1 reference

6 September 2017

page(s)

511-525

1 reference

describes a project that uses

6 September 2017

1 reference

https://scigraph.springernature.com/pub.10.1007/s00428-016-1910-4

0 references

cites work

European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Addressing the unmet need in lung cancer: The potential of immuno-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

ALK in lung cancer: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Immune checkpoint blockade: a common denominator approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

PD-L1 blockade for cancer treatment: MEDI4736.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

21 January 2018

PD-1/PD-L1 inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Programmed death ligand-1 expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Overall survival and PD-L1 expression in metastasized malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

PD-L1 expression in small cell neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

PD-L1 expression in small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Pitfalls in lung cancer molecular pathology: how to limit them in routine practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

L’accréditation selon la norme ISO 15189 d’un laboratoire de pathologie et de génétique somatique (LPCE, CHU de Nice) : retour d’expérience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1910-4

Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC

21 January 2018

1 reference

12 December 2020

PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the Same as Proof of Absence?

1 reference

12 December 2020

Frequent expression of PD-L1 on circulating breast cancer cells

1 reference

12 December 2020

[Immunohistochemistry and personalised medicine in lung oncology: advantages and limitations]

1 reference

12 December 2020

Immune checkpoint modulation for non-small cell lung cancer

1 reference

12 December 2020

PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development

1 reference

12 December 2020

Quantitative analysis of tumor in bronchial biopsy specimens

1 reference

12 December 2020

10.1007/S00428-016-1910-4

Identifiers

DOI

1 reference

6 September 2017

1 reference